Haleon - Gebro

Company snapshot

Bessere Gesundheit. Jeden Tag. Von Mensch zu Mensch. Nach der globalen Abspaltung der Consumer Healthcare Sparte der GSK, ist Haleon eines der weltweit führenden Consumer-Healthcare-Unternehmen. In Österreich bildet Haleon gemeinsam mit Gebro ein erfolgreiches Joint-Venture. Der Firmensitz von Haleon – Gebro befindet sich daher am Standort der Gebro Pharma GmbH in Fieberbrunn, Tirol. Zum Portfolio

• 1 approved product(s) across US/EU regulatory metadata.
• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Haleon - Gebro. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Haleon - Gebro.

1. Jun 8, 2026 Clinical update

   400314 — Phase 1

2. Jun 8, 2026 Clinical update

   300141 — Phase 1

3. Jun 8, 2026 Clinical update

   300128 — Approved

View all clinical trial activity →

• What is Haleon - Gebro?

  HALEON AUSTRALIA PTY is a pharma organization headquartered in AU. Primary therapeutic focus areas include Mild/non-serious osteoarthritis (OA) of the knee.. NovaPharmaNews links 3 clinical program(s), 1 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA,

• Is Haleon - Gebro publicly traded?

  Haleon - Gebro appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Haleon - Gebro develop or market?

  We link 9 drug profile(s) where Haleon - Gebro is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/haleon-ireland-dungarvan-limited#company-drugs.

• What are the latest developments for Haleon - Gebro?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Haleon - Gebro focus on?

  Haleon - Gebro focuses on Mild/non-serious osteoarthritis (OA) of the knee. based on our analysis of their pipeline programs and drug development activities.